{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:17:17Z","timestamp":1782764237170,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10067-021-05871-9","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T04:03:03Z","timestamp":1628827383000},"page":"123-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study"],"prefix":"10.1007","volume":"41","author":[{"given":"Bugra Han","family":"Egeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Ergun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya Kerem","family":"Gursoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-2282","authenticated-orcid":false,"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"issue":"18","key":"5871_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372(18):1734\u20131747","journal-title":"N Engl J Med"},{"issue":"5 Pt 1","key":"5871_CR2","first-page":"824","volume":"34","author":"LA Drake","year":"1996","unstructured":"Drake LA, Dinehart SM, Farmer ER et al (1996) Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 34(5 Pt 1):824\u2013829","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5871_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","volume":"28","author":"H Sasaki","year":"2018","unstructured":"Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28(6):913\u2013921","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5871_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1600-0404.1982.tb03087.x","volume":"65","author":"KG Henriksson","year":"1982","unstructured":"Henriksson KG, Sandstedt P (1982) Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand 65(4):280\u2013300","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"5871_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5871_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601\u2013607","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5871_CR7","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33(5):1021\u20131026","journal-title":"J Rheumatol"},{"issue":"7","key":"5871_CR8","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32(7):1369\u20131370","journal-title":"J Rheumatol"},{"issue":"12","key":"5871_CR9","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50(12):2206\u20132213","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5871_CR10","first-page":"1009","volume":"27","author":"R Rios-Fern\u00e1ndez","year":"2009","unstructured":"Rios-Fern\u00e1ndez R, Callejas Rubio JL, S\u00e1nchez Cano D, S\u00e1ez Moreno JA, Ortego Centeno N (2009) Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 27(6):1009\u20131016","journal-title":"Clin Exp Rheumatol"},{"key":"5871_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"issue":"1","key":"5871_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/kew146","volume":"56","author":"S Fasano","year":"2017","unstructured":"Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA (2017) Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 56(1):26\u201336","journal-title":"Rheumatology (Oxford)"},{"key":"5871_CR13","doi-asserted-by":"publisher","first-page":"960363","DOI":"10.1155\/2012\/960363","volume":"2012","author":"MF Baird","year":"2012","unstructured":"Baird MF, Graham SM, Baker JS, Bickerstaff GF (2012) Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. J Nutr Metab 2012:960363","journal-title":"J Nutr Metab"},{"issue":"6","key":"5871_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763\u2013767","journal-title":"Arch Dermatol"},{"issue":"9","key":"5871_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 62(9):1328\u20131334","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"5871_CR16","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","volume":"50","author":"M Couderc","year":"2011","unstructured":"Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50(12):2283\u20132289","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5871_CR17","first-page":"896","volume":"31","author":"F Mu\u00f1oz-Beamud","year":"2013","unstructured":"Mu\u00f1oz-Beamud F, Isenberg DA (2013) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31(6):896\u2013903","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5871_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10067-013-2449-2","volume":"34","author":"C Basnayake","year":"2015","unstructured":"Basnayake C, Cash K, Blumbergs P, Limaye V (2015) Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol 34(2):371\u2013377","journal-title":"Clin Rheumatol"},{"issue":"9","key":"5871_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","volume":"53","author":"L Unger","year":"2014","unstructured":"Unger L, Kampf S, L\u00fcthke K, Aringer M (2014) Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford) 53(9):1630\u20131638","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5871_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13317-014-0062-2","volume":"5","author":"G Vattemi","year":"2014","unstructured":"Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A et al (2014) Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights 5(3):77\u201385","journal-title":"Auto Immun Highlights"},{"key":"5871_CR21","first-page":"1335","volume-title":"Myology","author":"AG Engel","year":"2006","unstructured":"Engel AG, Hohlfeld R, Banker BQ (2006) The polymyositis and dermatomyositis syndrome. In: Engel AG, Franzini-Armstrong C (eds) Myology. New York: McGraw-Hill, pp 1335\u20131383"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05871-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05871-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T16:19:20Z","timestamp":1641313160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05871-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5871"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05871-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"23 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was exempt from the full board IRB review and got the IRB approval from Cerrahpasa Medical School IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}